Company Focus
Merck KGaA
Latest Merck KGaA News
Biotechnology
The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two years and above. 19 July 2025
Related News
Insights
Company Spotlight
A clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Latest News & Features of interest to Merck KGaA
Biotechnology
The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two years and above. 19 July 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy 2 mg for anaphylaxis treatment of adults and children (≥30 kg). 18 July 2025
Biotechnology
German mRNA specialist BioNTech has announced that Ryan Richardson will step down from his position as chief strategy officer and member of the management board. 18 July 2025
Biotechnology
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab mafodotin), sending shares in the UK drugmaker tumbling by 5% Friday. 18 July 2025
Generics
In what is not exactly a win-win situation for the Indian generic firms, a recent federal court ruling in Delaware, USA, has determined that MSN Pharmaceuticals has not infringed on a key patent (Novartis' US Patent No 11,096,918) related to Novartis' blockbuster heart failure drug, Entresto (sacubitril/valsartan). 18 July 2025
Biotechnology
US biotech TRIO Pharmaceuticals has announced the appointment of Patrick Doyle as chief executive (CEO effective immediately. 18 July 2025
Biotechnology
Scottish biotech Trogenix has announced two senior appointments as the company advances its pipeline towards the clinic. 18 July 2025
Pharmaceutical
The market for selective estrogen receptor modulators, or SERMs, is poised for considerable growth over the next decade, bolstered by innovation in targeted therapies and rising global awareness of women’s health. 18 July 2025
article
A panel of health experts has called on the US regulator to remove boxed warnings from vaginal estrogen treatments, arguing the safety notice is no longer backed by current evidence and discourages patients from accessing effective menopause care. 18 July 2025
Pharmaceutical
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
Latest In Brief for Merck KGaA
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
30 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze